Koffiekamer « Terug naar discussie overzicht

Amoeba-biocide.com Start-Up

144 Posts, Pagina: « 1 2 3 4 5 6 7 8 » | Laatste
MisterBlues
0
04/12/2020 | 18:11?Amoeba : Amoéba annonce l'émission de la 9° tranche d'obligations convertibles en actions

COMMUNIQUE DE PRESSE

AMOEBA annonce l'émission de la neuvième tranche de 26 obligations convertibles en actions dans le cadre de son financement obligataire avec programme d'intéressement conclu avec Nice & Green

Chassieu (France), le 4 décembre, 2020 - 17h45 - AMOÉBA (FR0011051598 - ALMIB),

producteur d'un biocide biologique capable d'éliminer le risque bactérien dans l'eau et les plaies humaines, et d'un produit de biocontrôle pour la protection des plantes, encore en phase de tests, annonce l'émission de la 9ème tranche d'obligations convertibles en actions (les « OCA ») de son financement obligataire avec programme d'intéressement, à savoir 26 OCA numérotées de 209 à 234 intégralement émises au profit de Nice & Green S.A.

Cette émission s'inscrit dans le cadre du contrat d'émission conclu avec Nice & Green S.A. le 17 décembre 2019 et d'un avenant n°1 au dit contrat conclu le 9 mars 2020, en vue de la mise en place d'un financement obligataire avec programme d'intéressement par émission de 312 OCA d'une valeur nominale de 20.000 euros chacune représentant un montant nominal total d'emprunt obligataire de 6.240.000 euros (le « Contrat d'Emission »)a.

Cette opération a fait l'objet d'un prospectus approuvé par l'AMF (visa n° 20-011) le 16 janvier 2020 (le « Prospectus »).

[...]

en PDF : www.amoeba-biocide.com/sites/default/...
Habsnurker
1
Amoeba : Amoéba extends to the USA the testing of its biocontrol products with GOWAN COMPANY


PRESS RELEASE

AMOEBA EXTENDS TO THE U.S.A. THE TESTING OF ITS BIOCONTROL

PRODUCTS WITH THE US GROUP GOWAN COMPANY

Chassieu (France), December 7, 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Material Transfer Agreement (MTA) with GOWAN COMPANY, a leading supplier of agricultural inputs (crop protection products, seeds and fertilizers) in the USA.

The purpose of the research partnership is the provision by Amoéba of experimental products containing the amoeba lysate Willaertia magna C2c Maky. In return, GOWAN COMPANY will carry out its own field trials to evaluate the performance of these products in preventing fungal diseases on a range of crops in the US market.

Amoéba and GOWAN COMPANY are thus embarking on a targeted research phase, which, if successful, could promote the commercial development of Amoéba biocontrol solutions in the USA

"This research partnership with a US company generating more than $500M in revenue materializes the first step in market engagement of Amoéba biocontrol products. It's perfectly aligned with the current assessment of our biocontrol dossier by the US authorities", explains Jean-Luc Souche - Amoéba Biocontrol Business Developer.

About GOWAN COMPANY

Gowan Company, based in Yuma, Arizona, USA, is a family-owned developer, registrant and marketer of crop protection products, seeds, and fertilizers. Gowan champions technology for agriculture and horticulture through innovative product development, public advocacy and quality production. Gowan's strong commitment to biologicals stems from their steadfast dedication to understanding and anticipating grower needs.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.
[verwijderd]
0
Vandaag in dubio gestaan maar toch iets anders gekocht. Jammer voor mij mooi nieuws voor jullie
mercurius-adept
0
ik las op frans forum reactie op dat PB, die google zo vertaalde:

"Test testen testen.....ze lijken nog niet echt bij de poort te staan ??om de toverdrank op de markt te brengen"

:)
MisterBlues
0
quote:

mercurius-adept schreef op 8 december 2020 09:28:

ik las op frans forum reactie op dat PB, die google zo vertaalde:

"Test testen testen.....ze lijken nog niet echt bij de poort te staan ??om de toverdrank op de markt te brengen"

:)
Het aandeel loopt nu enkel op verwachtingswaarde, inderdaad.

Ik plaats nog maar een keer de tijdlijnen van marktautorisatie.

Grove tijdlijnen van vermarkting biologische oplossingen voor de landbouw.
(Vanaf mei 2020)

Amoéba grapevinedowny mildew

(France), August11 2020- the publication of a first scientific article on its biocontrol application(https://www.mdpi.com/2223-7747/9/8/1013/pdf)in the special issue« Natural Products for Plant Pest and Disease Control» ofPlants, journal of theMDPIGroup, peer-reviewed.

As a reminder, the marketing of biocontrol products containing this active substance is envisaged by Amoéba in 2024 in Europe (dossier submitted, cf. Press Release of 29 May 2020) and in the first half of 2022 in the United States (submission envisaged in July 2020, cf. Press Release of 29 April 2020, postponed to September 2020).

The prioritization of Amoéba's Regulatory Affairs Department resources on biocontrol application leads to a delay in the filing of a new application for biocidal application in the United States, which was envisaged in mid 2020 (see Universal Registration Document of April 30, 2020) and will be submitted at the end of 2020, with first marketing in the United States estimated in the first half of 2022.

Amoeba Fungicidal use in agriculture

The biocontrol solution, developed by Amoéba, is intended for a fungicidal use in agriculture.

A possible approval mid-2023 The dossier submission is in line with Amoébatime schedule. The approval procedure that is starting will take between 2.5 and 3.5 years, with an expected decision in 2023.

The main steps are as follows:

•Evaluation phase by the rapporteur Member State (approximately 14 months): at the end of which the draft report is submitted to the European Food Safety Authority (EFSA).

•Risk assessment phase (7 to 11 months): EFSA carries out the risk assessment and risk communication on food safety aspects and then organises an consultation with experts and publishes a scientific report containing its conclusions.

•Risk management phase (9 to 12 months): the European Commission presents a draft regulation to the Standing Committee on the Food Chain and Animal Health, which ultimately votes on the approval or non-approval of the active substance. In general, an active substance is approved for a period of 10 years, or even 15 years if it is classified as "low risk".

These timeframes could be reduced depending on the deployment of the “Farm to Fork Strategy” strategy of the European Commission (published on May 20th, 20202) who “will also facilitate the placing on the market of pesticides containing biological active substancesand[...] will act to reduce the length of the pesticide authorisation process by Member States”
MisterBlues
0
quote:

Kleintje66 schreef op 7 december 2020 21:49:

Vandaag in dubio gestaan maar toch iets anders gekocht. Jammer voor mij mooi nieuws voor jullie
Wat heb je dan gekocht? Waarom is dit mooi nieuws voor ons?

Je maakt me nieuwsgierig door zo weinig prijs te geven...
MisterBlues
1
quote:

Lego schreef op 8 december 2020 13:46:

Vanwaar de sterke daling ? Is er nieuws ?
Na zo'n ongekende stijging moest er een keer wat lucht uit. Geen nieuws of tegenslag. Voor mij is het belangrijkste dat ie nu boven de 3 euro blijft en derhalve zijn pennystock imago verliest.
[verwijderd]
1
quote:

MisterBlues schreef op 8 december 2020 10:41:

[...]

Wat heb je dan gekocht? Waarom is dit mooi nieuws voor ons?

Je maakt me nieuwsgierig door zo weinig prijs te geven...
Ik dacht dat wel positief gereageerd zou worden op het nieuws. Gisteren niet gekocht vanwege de stijgingen de afgelopen tijd. Dat laatste blijkbaar goed ingeschat dat eerste niet.
Habsnurker
2
Amoéba signs an exclusive development and marketing agreement in France with PHILAGRO for its grapevine biocontrol product

PRESS RELEASE

AMOEBA SIGNS AN EXCLUSIVE DEVELOPMENT AND MARKETING AGREEMENT

IN FRANCE WITH PHILAGRO FOR ITS GRAPEVINE BIOCONTROL PRODUCT

Chassieu (France), December 9, 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Letter of Intent (LOI) with PHILAGRO France, concerning the development and marketing of its biocontrol product against vine downy mildew in France.

This signature, with a recognised player in the crop protection market, an entity born from the strategic alliance of three Japanese groups (SUMITOMO Chemical Company, NISSAN Chemical Industries and NIHON NOHYAKU Company), follows on from the partnership announced in April 2020 to evaluate the performance of the biocontrol fungicide containing AMOEBA's active substance: the amoeba lysate Willaertia magna C2c Maky.

The aim of the LOI is to define the collaboration outlines between the two companies before and after the marketing of the product on the French territory with a view to signing a commercial partnership contract within 12 months.

Amoéba will carry out the regulatory tests necessary for the registration of its product and PHILAGRO will refine the marketing and commercial positioning of the product through field trials.

Amoéba has made an exclusive commitment with PHILAGRO France concerning vine application over a marketing period of several years in France, the leading European market for downy mildew treatment.

"The Philagro team is delighted to be able to work with Amoéba for the development and future marketing of this very promising biocontrol solution in the strategic segment of the vine downy mildew. The two companies share a common vision of the evolution of the French market and high expectations in biocontrol innovations, complementing each other perfectly to make this solution a real technical and commercial success" explains Denis TROALEN, General Manager of PHILAGRO France.

"The choice of PHILAGRO as an exclusive partner is guided by more than 25 years of experience in the service of crop protection, a strong operational positioning in biocontrol and a real capacity for commercial execution in this strategic segment. The human relationship established between our two companies during this 2020 year of field tests has convinced us of the unfailing motivation of the teams to make the most of our product against vine downy mildew in France. "comments Fabrice PLASSON, Chairman and CEO of Amoéba.
MisterBlues
1
Populaire aandelen zijn wonderbaarlijk niet per se ook echt winstgevende aandelen.
(Pharming, Galap.)

Waarom doe jij niet wat onderzoek en maak een leuke post hier?
mercurius-adept
0
Chassieu (France), December 18, 2020

AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Term Sheet with STÄHLER SUISSE SA, for the development and marketing of its biocontrol product against vine downy mildew in Switzerland.
Bijlage:
[verwijderd]
0
quote:

MisterBlues schreef op 17 december 2020 09:14:

Populaire aandelen zijn wonderbaarlijk niet per se ook echt winstgevende aandelen.
(Pharming, Galap.)

Waarom doe jij niet wat onderzoek en maak een leuke post hier?
Heb wat onderzoek gedaan en wat linkjes doorgenomen die hier gepost zijn. lijkt me een mooie aandeel voor de lange termijn. Heb er 900 op de plank gelegd.
mercurius-adept
0
AMOEBA RENEWS A FINANCING LINE OF UP TO €23M WITH NICE & GREEN TO
SUPPORT ITS DEVELOPMENT

Chassieu (France), December 21, 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a new contract for the issue of bonds convertible into shares with a profit-sharingprogramme (OCAPI) and a subordination agreement between Amoéba, Nice & Green SA and the European Investment Bank (EIB).

This new 24-month financing line is intended to give Amoéba the means to finance its key activities, in particular the development of its biocontrol product, and to restructure its debt.

www.marketscreener.com/quote/stock/AM...
Freemoneyforever
0
quote:

€URO-Trader schreef op 28 december 2020 23:00:

Koers is dalende.Afwachtende houding....
Wat is de reden?
MisterBlues
0
Er is gewoon luwte. Logisch dat de koers daalt na zo'n enorme klim, geholpen door KT-handelaren.

Het spannende nu is of het blijft hangen rond de drie euro. Het ziet er wel zo uit. Dan kan het aandeel eindelijk een keer het jaar record voorbij als er weer goed nieuws is. (Duurt nog even.)
Freemoneyforever
0
Dank je, laten we het in de gaten houden, er ontstaan (op termijn) dus instapmomenten, de vraag is wanneer, begrijp ik, MisterBlues.
144 Posts, Pagina: « 1 2 3 4 5 6 7 8 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 875,30 -8,77 -0,99% 15:04
AMX 922,06 -9,23 -0,99% 15:04
ASCX 1.218,93 -10,66 -0,87% 14:49
BEL 20 3.788,10 -65,64 -1,70% 15:04
Germany40^ 17.833,20 -193,38 -1,07% 15:04
US30^ 37.951,70 +253,04 +0,67% 14:34
US500^ 5.070,74 +9,88 +0,20% 15:00
Nasd100^ 17.716,80 +23,14 +0,13% 15:04
Japan225^ 38.551,12 -146,64 -0,38% 15:00
WTI 84,42 -0,64 -0,75% 15:04
Brent 89,59 -0,67 -0,74% 15:04
EUR/USD 1,0636 +0,0011 +0,11% 15:04
BTC/USD 62.957,56 -3.255,35 -4,92% 15:04
Gold spot 2.373,38 -9,77 -0,41% 15:04
#/^ Index indications calculated real time, zie disclaimer
HOGE RENDEMENTEN OP DE IEX-MODELPORTEFEUILLES > WORD NU ABONNEE EN PROFITEER VAN MAAR LIEFST 67% KORTING!

Stijgers & Dalers

Stijgers Laatst +/- % tijd
DSM FIRMENICH AG 102,300 +1,500 +1,49% 14:45
Philips Koninklijke 19,405 +0,010 +0,05% 14:46
Akzo Nobel 65,860 -0,080 -0,12% 14:46
Dalers Laatst +/- % tijd
ArcelorMittal 23,900 -1,620 -6,35% 14:46
RANDSTAD NV 47,340 -1,190 -2,45% 14:46
ASMI 590,400 -12,800 -2,12% 14:46

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront